Literature DB >> 20142806

Disruption of sarcolemmal dystrophin and beta-dystroglycan may be a potential mechanism for myocardial dysfunction in severe sepsis.

Mara Rúbia N Celes1, Diego Torres-Dueñas, Lygia M Malvestio, Valdecir Blefari, Erica C Campos, Simone G Ramos, Cibele M Prado, Fernando Q Cunha, Marcos A Rossi.   

Abstract

Evidence from our laboratory has shown alterations in myocardial structure in severe sepsis/septic shock. The morphological alterations are heralded by sarcolemmal damage, characterized by increased plasma membrane permeability caused by oxidative damage to lipids and proteins. The critical importance of the dystrophin-glycoprotein complex (DGC) in maintaining sarcolemmal stability led us to hypothesize that loss of dystrophin and associated glycoproteins could be involved in early increased sarcolemmal permeability in experimentally induced septic cardiomyopathy. Male C57Bl/6 mice were subjected to sham operation and moderate (MSI) or severe (SSI) septic injury induced by cecal ligation and puncture (CLP). Using western blot and immunofluorescence, a downregulation of dystrophin and beta-dystroglycan expression in both severe and moderate injury could be observed in septic hearts. The immunofluorescent and protein amount expressions of laminin-alpha2 were similar in SSI and sham-operated hearts. Consonantly, the evaluation of plasma membrane permeability by intracellular albumin staining provided evidence of severe injury of the sarcolemma in SSI hearts, whereas antioxidant treatment significantly attenuated the loss of sarcolemmal dystrophin expression and the increased membrane permeability. This study offers novel and mechanistic data to clarify subcellular events in the pathogenesis of cardiac dysfunction in severe sepsis. The main finding was that severe sepsis leads to a marked reduction in membrane localization of dystrophin and beta-dystroglycan in septic cardiomyocytes, a process that may constitute a structural basis of sepsis-induced cardiac depression. In addition, increased sarcolemmal permeability suggests functional impairment of the DGC complex in cardiac myofibers. In vivo observation that antioxidant treatment significantly abrogated the loss of dystrophin expression and plasma membrane increased permeability supports the hypothesis that oxidative damage may mediate the loss of dystrophin and beta-dystroglycan in septic mice. These abnormal parameters emerge as therapeutic targets and their modulation may provide beneficial effects on future cardiovascular outcomes and mortality in sepsis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142806     DOI: 10.1038/labinvest.2010.3

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  12 in total

1.  Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy.

Authors:  Byung-Kwan Lim; Angela K Peter; Dingding Xiong; Anna Narezkina; Aaron Yung; Nancy D Dalton; Kyung-Kuk Hwang; Toshitaka Yajima; Ju Chen; Kirk U Knowlton
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

2.  Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis.

Authors:  Xiaohong Wang; Wei Huang; Yang Yang; Yigang Wang; Tianqing Peng; Jiang Chang; Charles C Caldwell; Basilia Zingarelli; Guo-Chang Fan
Journal:  Biochim Biophys Acta       Date:  2014-01-29

3.  Analysis on sarcoglycans expression as markers of septic cardiomyopathy in sepsis-related death.

Authors:  Elvira Ventura Spagnolo; Cristina Mondello; Debora Di Mauro; Giovanna Vermiglio; Alessio Asmundo; Elena Filippini; Angela Alibrandi; Giuseppina Rizzo
Journal:  Int J Legal Med       Date:  2018-04-11       Impact factor: 2.686

4.  Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition.

Authors:  Ana Caroline Silva Freitas; Maria Jose Figueiredo; Erica Carolina Campos; Danilo Figueiredo Soave; Simone Gusmao Ramos; Herbert B Tanowitz; Mara Rúbia N Celes
Journal:  PLoS One       Date:  2016-11-23       Impact factor: 3.240

5.  Early dystrophin loss is coincident with the transition of compensated cardiac hypertrophy to heart failure.

Authors:  Fernanda P Prado; Daniele O Dos Santos; Valdecir Blefari; Carlos A Silva; Juliano Machado; Isis do Carmo Kettelhut; Simone G Ramos; Marcelo Dias Baruffi; Helio C Salgado; Cibele M Prado
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

6.  Effect of Verapamil, an L-Type Calcium Channel Inhibitor, on Caveolin-3 Expression in Septic Mouse Hearts.

Authors:  Bruna A C Rattis; Ana C Freitas; Jordana F Oliveira; João L A Calandrini-Lima; Maria J Figueiredo; Danilo F Soave; Simone G Ramos; Mara R N Celes
Journal:  Oxid Med Cell Longev       Date:  2021-04-08       Impact factor: 6.543

7.  An Autopsy Case of Fulminant, Suppurative Bacterial Myocarditis Caused by Group B Streptococcus.

Authors:  Ryuta Nakashima; Munenori Kotoku; Ayako Gamachi; Nobuhiro Inagaki; Shunji Kasaoka
Journal:  Intern Med       Date:  2021-09-18       Impact factor: 1.271

8.  Disruption of calcium homeostasis in cardiomyocytes underlies cardiac structural and functional changes in severe sepsis.

Authors:  Mara R N Celes; Lygia M Malvestio; Sylvia O Suadicani; Cibele M Prado; Maria J Figueiredo; Erica C Campos; Ana C S Freitas; David C Spray; Herbert B Tanowitz; João S da Silva; Marcos A Rossi
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

Review 9.  Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature.

Authors:  Robert R Ehrman; Ashley N Sullivan; Mark J Favot; Robert L Sherwin; Christian A Reynolds; Aiden Abidov; Phillip D Levy
Journal:  Crit Care       Date:  2018-05-04       Impact factor: 9.097

10.  Elevated Cardiac Troponin in Clinical Scenarios Beyond Obstructive Coronary Artery Disease.

Authors:  Michael Sternberg; Evasio Pasini; Carol Chen-Scarabelli; Giovannii Corsetti; Hemang Patel; Daniele Linardi; Francesco Onorati; Giuseppe Faggian; Tiziano Scarabelli; Louis Saravolatz
Journal:  Med Sci Monit       Date:  2019-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.